Compare VFF & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VFF | LXEO |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.1M | 348.7M |
| IPO Year | 2013 | 2023 |
| Metric | VFF | LXEO |
|---|---|---|
| Price | $2.73 | $3.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.83 | ★ $20.30 |
| AVG Volume (30 Days) | 701.6K | ★ 1.6M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | 39.81 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $215,937,000.00 | $654,000.00 |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $20.22 | N/A |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $2.98 |
| 52 Week High | $4.99 | $10.99 |
| Indicator | VFF | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 34.49 |
| Support Level | $2.49 | $2.98 |
| Resistance Level | $3.18 | $5.38 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 6.98 | 26.79 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.